Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50-Day Moving Average – Time to Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $8.31 and traded as high as $9.09. Theravance Biopharma shares last traded at $8.91, with a volume of 184,700 shares traded.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a research note on Monday, September 16th. Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. Finally, TD Cowen reduced their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Trading Down 1.9 %

The stock’s 50-day moving average is $8.31 and its 200 day moving average is $8.68.

Institutional Trading of Theravance Biopharma

A number of institutional investors have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. grew its stake in shares of Theravance Biopharma by 41.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock valued at $5,005,000 after buying an additional 163,951 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Theravance Biopharma by 38.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after purchasing an additional 91,679 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Theravance Biopharma by 83.6% in the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after purchasing an additional 135,426 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in Theravance Biopharma by 12.6% in the third quarter. GSA Capital Partners LLP now owns 229,780 shares of the biopharmaceutical company’s stock worth $1,852,000 after purchasing an additional 25,691 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in Theravance Biopharma by 6.3% during the first quarter. SG Americas Securities LLC now owns 209,566 shares of the biopharmaceutical company’s stock worth $1,880,000 after buying an additional 12,460 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.